Novoigf
LR3 1mg KIT
NOVOIGF Insulin-like Growth Factor 1 Long LR3 contains:
- 10 vials of Recombinant Human IGF1 LR3
- 100mcg each vial
- 83 Amino Acid
- 10mL Bacteriostatic Water for Injection USP
Novoigf LR3 is a medical quality Somatomedin C also called IGF1 LR3 (Insulin-like Growth Factor 1 Long R3), it’s more powerful than the typical IGF-1 peptide which plays an important role in cells growth and provides the following effects:
- Increased lipolysis (fat burning)
- Supports cardiovascular function
- Lowers LDL
- Has a positive effect on cartilage
- Supports mental wellbeing by increasing levels of the neurotransmitter serotonin
- Increases muscle mass and strength
- Proven highly effective for localized use.
- Benefits tissue regeneration (accelerates the healing of injuries)
NOVOIGF Insulin-like Growth Factor 1 Long LR3 contains:
– 10 vials of Recombinant Human IGF1 LR3
– 100mcg each vial
– 83 Amino Acid
– 10mL Bacteriostatic Water for Injection USP
Novoigf LR3 is a medical quality Somatomedin C also called IGF1 LR3 (Insulin-like Growth Factor 1 Long R3), it’s more powerful than the typical IGF-1 peptide which plays an important role in cells growth and provides the following effects:
- Increased lipolysis (fat burning)
- Supports cardiovascular function
- Lowers LDL
- Has a positive effect on cartilage
- Supports mental wellbeing by increasing levels of the neurotransmitter serotonin
- Increases muscle mass and strength
- Proven highly effective for localized use.
- Benefits tissue regeneration (accelerates the healing of injuries)
Novoigf
LR3 1mg KIT
About
Novoigf LR3, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1). It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence (“arginine 3”), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (“long”), for a total of 83 amino acids (relative to the 70 of IGF-1).
The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability. As a result, it is approximately three times more potent than IGF-1, and possesses a significantly longer half-life of about 20–30 hours (relative to IGF-1’s half-life of about 12–15 hours).